Abstract: The invention is directed to an intratumor injectable formulation, a method of making the intratumor injectable formulation and a method of treating a malignant mass in a mammal by administering the injectable formulation directly into the malignant mass. The injectable intratumor formulation may be an emulsion, solution or suspension, all of which comprise a therapeutically effective amount of a basic chemotherapeutic drug dissolved or suspended in a biocompatible carrier, wherein the basic chemotherapeutic drug is an anthracycline base, a vina alkaloid base, an eribulin base or an alkylating agent base.

Abstract: Formulations and uses of the formulations for treating a malignant mass in a mammal by administering an injectable formulation comprising a therapeutically effective amount of a chemotherapeutic agent dissolved or suspended in a biocompatible carrier directly into the malignant mass are disclosed. In certain preferred embodiments, the injectable formulation is a taxane (e.g. paclitaxel), a podophyllotoxin derivative (e.g., etoposide), or a camptothecin derivative (e.g., hydroxycamptothecin).

Abstract: The invention is directed to an intratumor injectable formulation, a method of making the intratumor injectable formulation and a method of treating a malignant mass in a mammal by administering the injectable formulation directly into the malignant mass. The injectable intratumor formulation may be an emulsion, solution or suspension, all of which comprise a therapeutically effective amount of a basic chemotherapeutic drug dissolved or suspended in a biocompatible carrier, wherein the basic chemotherapeutic drug is an anthracycline base, a vina alkaloid base, an eribulin base or an alkylating agent base.

Abstract: Formulations and uses of the formulations for treating a malignant mass in a mammal by administering an injectable formulation comprising a therapeutically effective amount of a chemotherapeutic agent dissolved or suspended in a biocompatible carrier directly into the malignant mass are disclosed. In certain preferred embodiments, the injectable formulation is a taxane (e.g. paclitaxel), a podophyllotoxin derivative (e.g., etoposide), or a camptothecin derivative (e.g., hydroxycamptothecin).